McDonnell Boehnen Hulbert & Berghoff LLP partner Kevin Noonan, Ph.D. is quoted in a May 9, 2018 BioWorld article entitled, “USPTO rule change could end PTAB’s reputation as a patent killer.” Wishes do come true. The U.S. Patent and Trademark Office (USPTO) is proposing a rule that would align the standard the Patent Trial and Appeal Board (PTAB) uses in interpreting claims in inter partes review (IPR), post-grant review and covered-business method proceedings with that of the courts. view the article
